El Khashab, M., Emam, M., Assad, M., Abd Elraziq, A. (2015). Study the Role of Prometheus Index in Prediction of Response to Treatment in Hepatitis C Patients of Genotype 4. Afro-Egyptian Journal of Infectious and Endemic Diseases, 5(4), 207-217. doi: 10.21608/aeji.2015.17841
Mohammad N El Khashab; Mohammad Emam; Marian Assad; Ahmed M Abd Elraziq. "Study the Role of Prometheus Index in Prediction of Response to Treatment in Hepatitis C Patients of Genotype 4". Afro-Egyptian Journal of Infectious and Endemic Diseases, 5, 4, 2015, 207-217. doi: 10.21608/aeji.2015.17841
El Khashab, M., Emam, M., Assad, M., Abd Elraziq, A. (2015). 'Study the Role of Prometheus Index in Prediction of Response to Treatment in Hepatitis C Patients of Genotype 4', Afro-Egyptian Journal of Infectious and Endemic Diseases, 5(4), pp. 207-217. doi: 10.21608/aeji.2015.17841
El Khashab, M., Emam, M., Assad, M., Abd Elraziq, A. Study the Role of Prometheus Index in Prediction of Response to Treatment in Hepatitis C Patients of Genotype 4. Afro-Egyptian Journal of Infectious and Endemic Diseases, 2015; 5(4): 207-217. doi: 10.21608/aeji.2015.17841
Study the Role of Prometheus Index in Prediction of Response to Treatment in Hepatitis C Patients of Genotype 4
1Tropical Medicine Department, Faculty of Medicine, Zagazig University, Egypt
2Medical Microbiology and Imunology Department, Faculty of Medicine, Zagazig University, Egypt
Abstract
Background and study aim : Because of pegylated interferon (Peg-IFN)/ribavirin therapy is poorly tolerated and rates of response are lower in hepatitis C virus (HCV) infected patients of genotype 4, the recognition of predictors of response is a high priority in this population. We aimed to use a baseline noninvasive index to predict early virological response (EVR) to Peg-IFN/ribavirin in HCV-infected individuals, the score included 4 variables: 2 host-related variables (IL28B SNP rs12979860 and liver stiffness) and 2 HCV-related variables (genotype and viral load). Patients and Methods: 96 treatment-naive HCV-infected patients receiving Peg-IFN/ribavirin were analysed and predictive model was used. The areas under the receiver operating characteristic (AUROC) curves (95% CI), sensitivity and specificity, as well as negative and positive predictive values, were calculated. Only individuals who had completed a course of Peg-IFN-RBV therapy were considered. Results: EVR was achieved in (60.4 %) of patients. The area under the receiver operating characteristic curve (AUROC) was 0.849 (0.762-0.914). Using three cut-off values, maximum specificity and sensitivity were 81.5% and 77.5%, respectively, with a negative predictive value for EVR of 80% and a positive predictive value of 83.6%. Seventeen individuals were misclassified using optimal cut-off values. Conclusion: The probability of achieving EVR with Peg-IFN-RBV therapy in HCV-infected patients can be reliably estimated prior to initiation of therapy using Prometheusindex that includes 4 noninvasive parameters. Prometheusindex represents a reliable and easily applicable tool to individually evaluate the probability of achieving an EVR to Peg-IFN/ribavirin among HCV-infected patients.
View on SCiNiTO
Top